| | 118288-08-7 Basic information More.. |
| Product Name: | Lafutidine | | Synonyms: | n-(4-(4-piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide;2-((Furan-2-ylMethyl)sulfinyl)-N-(4-((4-(piperidin-1-ylMethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetaMide;(Z)-2-((Furan-2-ylMethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylMethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetaMide;Adefovir Dipivioxil;(Z)-2-((Furan-2-ylmethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-yl);(Z)-2-((Furan-2-ylmethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-;LAFUTIDINE(SUBJECTTOPATENTFREE);118288-08-07 | | CAS: | 118288-08-7 | | MF: | C22H29N3O4S | | MW: | 431.55 | | EINECS: | 601-513-8 | | Mol File: | 118288-08-7.mol |  |
Use
Lafutidine is a second generation of H2-receptor antagonist. H2-receptor antagonist can strongly inhibit gastric acid secretion compared with conventional drugs such as antacids. Unlike conventional H2-receptor antagonist, lafutidine inhibits gastric acid secretion during daytime as well as nighttime in clinical studies in humans. Lafutidine also has gastroprotective activity independent of its acid antisecretory efficacy, preventing noxious agent-induced gastric mucosal injury and accelerating the repair process following gastric mucosal damage. It also protects experimentally induced reflux esophagitis, indomethacin-induced intestinal, and dextran sulfate sodium-induced colonic inflammation.
Lafutidine is used for gastric and duodenal ulcers. It is also confirmed that lafutidine can be used as an empiric treatment and superior efficacy for primary care practice patients with dyspepsia.
- Lafutidine
-
- US $66.00-41.00 / mg
- 2025-07-29
- CAS:118288-08-7
- Min. Order:
- Purity: 100.00%
- Supply Ability: 10g
- Lafutidine
-
- 2025-07-28
- CAS:118288-08-7
- Min. Order:
- Purity: 0.99
- Supply Ability:
- Lafutidine
-
- US $0.00 / Kg/Bag
- 2025-07-28
- CAS:118288-08-7
- Min. Order: 10g
- Purity: 98.5%min
- Supply Ability: 10kg
|
|
118288-08-7
Recommend Suppliers |
|